ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,646,535 | -21.6% | 4,741,362 | +11.2% | 0.00% | – |
| Q2 2023 | $5,925,938 | -13.7% | 4,263,265 | -1.3% | 0.00% | – |
| Q1 2023 | $6,866,397 | -74.1% | 4,318,489 | +1.4% | 0.00% | -100.0% |
| Q4 2022 | $26,542,691 | -1.9% | 4,260,464 | +5.5% | 0.00% | 0.0% |
| Q3 2022 | $27,059,000 | -1.0% | 4,038,525 | -6.0% | 0.00% | 0.0% |
| Q2 2022 | $27,323,000 | +31.1% | 4,296,198 | -4.3% | 0.00% | – |
| Q1 2022 | $20,841,000 | +10.8% | 4,491,530 | +19.4% | 0.00% | – |
| Q4 2021 | $18,808,000 | -15.2% | 3,761,439 | +104.4% | 0.00% | -100.0% |
| Q3 2021 | $22,175,000 | -54.4% | 1,840,243 | -20.0% | 0.00% | 0.0% |
| Q2 2021 | $48,644,000 | -25.2% | 2,299,988 | -0.8% | 0.00% | -50.0% |
| Q1 2021 | $65,051,000 | +5.8% | 2,319,113 | -2.0% | 0.00% | 0.0% |
| Q4 2020 | $61,498,000 | -28.2% | 2,365,307 | +2.6% | 0.00% | -33.3% |
| Q3 2020 | $85,652,000 | -29.3% | 2,304,347 | -2.4% | 0.00% | -25.0% |
| Q2 2020 | $121,177,000 | +55.0% | 2,361,653 | -4.8% | 0.00% | +33.3% |
| Q1 2020 | $78,196,000 | -50.5% | 2,480,112 | -6.3% | 0.00% | -40.0% |
| Q4 2019 | $157,894,000 | +61.4% | 2,647,911 | -0.8% | 0.01% | +25.0% |
| Q3 2019 | $97,825,000 | -6.4% | 2,668,463 | +18.7% | 0.00% | 0.0% |
| Q2 2019 | $104,543,000 | +48.2% | 2,247,286 | +27.9% | 0.00% | +33.3% |
| Q1 2019 | $70,560,000 | -9.7% | 1,757,423 | +3.5% | 0.00% | -25.0% |
| Q4 2018 | $78,112,000 | +6.7% | 1,698,070 | +3.0% | 0.00% | +33.3% |
| Q3 2018 | $73,173,000 | +20.5% | 1,649,168 | +6.5% | 0.00% | 0.0% |
| Q2 2018 | $60,715,000 | -43.5% | 1,549,222 | +4.3% | 0.00% | -40.0% |
| Q1 2018 | $107,414,000 | +75.3% | 1,485,046 | +59.6% | 0.01% | +66.7% |
| Q4 2017 | $61,263,000 | +38.9% | 930,481 | +5.7% | 0.00% | +50.0% |
| Q3 2017 | $44,121,000 | +26.1% | 880,323 | +16.4% | 0.00% | 0.0% |
| Q2 2017 | $34,997,000 | +36.9% | 756,224 | +4.4% | 0.00% | +100.0% |
| Q1 2017 | $25,569,000 | +239.9% | 724,150 | +20.5% | 0.00% | – |
| Q4 2016 | $7,522,000 | -4.4% | 600,832 | +5.7% | 0.00% | – |
| Q3 2016 | $7,870,000 | -1.9% | 568,203 | -30.0% | 0.00% | – |
| Q2 2016 | $8,020,000 | -35.6% | 811,704 | +10.2% | 0.00% | -100.0% |
| Q1 2016 | $12,459,000 | -22.9% | 736,776 | +1.5% | 0.00% | 0.0% |
| Q4 2015 | $16,161,000 | -95.1% | 726,070 | -92.8% | 0.00% | -91.7% |
| Q3 2015 | $327,674,000 | +465.8% | 10,134,882 | +1330.8% | 0.01% | +200.0% |
| Q2 2015 | $57,912,000 | +57.8% | 708,323 | +78.7% | 0.00% | +100.0% |
| Q1 2015 | $36,700,000 | +263.5% | 396,320 | +58.8% | 0.00% | +100.0% |
| Q4 2014 | $10,095,000 | +158.8% | 249,618 | +56.5% | 0.00% | – |
| Q3 2014 | $3,900,000 | +55.0% | 159,455 | +0.4% | 0.00% | – |
| Q2 2014 | $2,516,000 | +4.8% | 158,836 | +0.1% | 0.00% | – |
| Q1 2014 | $2,400,000 | +28.0% | 158,717 | +16.3% | 0.00% | – |
| Q4 2013 | $1,875,000 | +34.5% | 136,415 | +84.6% | 0.00% | – |
| Q3 2013 | $1,394,000 | – | 73,890 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |